Medindia3d
Abilita Therapeutics and Orion Announce Research Collaboration to Develop Next-Generation Antibody Therapeutics in the Areas of Oncology and Pain
Abilita Therapeutics, Inc. ("Abilita") today announced a global licensing and multi-target research collaboration with Finnish Orion Corporation ("Orion") focused on the discovery, development and ...
ENDPOINTS NEWS4d
Gilead deep­ens its stake in As­sem­bly Bio­sciences; NGM li­cens­es out MASH drug
Plus, news about Abilita Therapeutics, Orion, Novartis, XGEN Venture, Palleon, Henlius, TigaTx, HERVolution Therapeutics and Krystal Biotech: ...
Finanznachrichten5d
Orion Oyj: Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics
Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics Orion Corporation ("Orion") and Abilita Therapeutics ...
manilatimes5d
Bureau raises $30M Series B as global fraud losses hit $486B
Risk intelligence platform sees 3x revenue growth as the surge in sophisticated fraud attacks drive demand for AI-powered ...
Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics
ORION CORPORATION PRESS RELEASE 18 DECEMBER 2024 at 17.00 EET Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics ...
Le Lézard5d
Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Vir Biotechnology Inc. today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, at ...
Le Lézard5d
Holoclara Selects Eosinophilic Esophagitis as its Lead Indication for HC002, a First-in-Class Worm-Derived Therapy
Holoclara, a biotechnology company pioneering the development of worm-derived therapies for allergic and autoimmune disorders, today announced the selection of eosinophilic esophagitis (EoE) as its ...
Seeking Alpha24d
Applied Therapeutics stock craters 75% on FDA setback
Applied Therapeutics shares (NASDAQ:APLT) were down 75% early Friday, the first trading session after the company announced the FDA had declined to approve its drug govorestat for the treatment of ...
Wall Street Journal25d
Revance Therapeutics Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Business Insider26d
Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Madrigal Pharmaceuticals (MDGL)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Axsome Therapeutics (AXSM – Research Report), Madrigal Pharmaceuticals (MDGL – Research Report ...
Investing26d
FDA declines approval for Applied Therapeutics' Galactosemia drug
NEW YORK - Applied Therapeutics Inc . (NASDAQ:APLT), a biopharmaceutical company, received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug ...
Investing26d
Outlook Therapeutics reports NORSE EIGHT trial results; shares slump
Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company, today announced preliminary topline results from its NORSE EIGHT clinical trial, which evaluated ONS-5010 for the treatment ...